Format

Send to:

Choose Destination
See comment in PubMed Commons below
AAPS J. 2007 Mar 23;9(1):E105-8.

Biomarker qualification pilot process at the US Food and Drug Administration.

Author information

  • 1Genomics Group, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903-0002, USA. Federico.goodsaid@fda.hhs.gov

Abstract

New biomarkers of safety and efficacy are becoming powerful tools in drug development. Their application can be accelerated if a consensus can be reached about their qualification for regulatory applications. This consensus requires a review structure within the US Food and Drug Administration (FDA) that can evaluate qualification data for these biomarkers and determine whether these biomarkers can be qualified. A pilot process and corresponding Biomarker Qualification Review Team have been developed to test how the FDA can work on biomarker qualification.

PMID:
17408233
[PubMed - indexed for MEDLINE]
PMCID:
PMC2751298
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk